Genome Biologics Overview

  • Founded

  • 2016

Founded
  • Status

  • Private

  • Employees

  • 12

Employees
  • Latest Deal Type

  • Grant

  • Investors

  • 3

Genome Biologics General Information

Description

Developer of a drug-disease matching platform designed to facilitate efficient and ethical drug development and positioning. The company's platform leverage the power of AI-based machine learning with a transformative single cell in vitro and in vivo transgenesis to identify new compounds or to repurpose known compounds for the treatment of cardiovascular and cardiometabolic and cancer, enabling medical researchers to reduce the cost, time, and ethical burden of preclinical research.

Contact Information

Website
www.genomebiologics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Other Healthcare Technology Systems
Primary Office
  • Centre for Molecular Medicine, Goethe-Universit
  • Theodor-Stern-Kai 7
  • 60590 Frankfurt
  • Germany
+49 069 000000000

Genome Biologics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genome Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 000.00 Completed Pre-Clinical Trials
4. Later Stage VC 20-Dec-2021 000.00 000.00 Completed Pre-Clinical Trials
3. Grant 31-Aug-2021 00.000 Completed Pre-Clinical Trials
2. Grant 09-Apr-2018 $61.6K Completed Pre-Clinical Trials
1. Accelerator/Incubator 23-Mar-2018 Completed Pre-Clinical Trials
To view Genome Biologics’s complete valuation and funding history, request access »

Genome Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug-disease matching platform designed to facilitate efficient and ethical drug development and position
Discovery Tools (Healthcare)
Frankfurt, Germany
12 As of 2022
000.00
00000 000.00

000000

ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis au
000000000 00000 (000
Oxford, United Kingdom
000 As of 0000
00000
000000000 00000

000000

cing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
London, United Kingdom
000 As of 0000
00000
0.000 0000-00-00
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genome Biologics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exscientia Formerly VC-backed Oxford, United Kingdom 000 00000 000000000 00000
000000000000 Formerly PE-Backed London, United Kingdom 000 00000 000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

Genome Biologics Patents

  • 7

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Genome Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4025693-A1 Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure Pending 05-Sep-2019 000000000
US-20220332845-A1 Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure Pending 05-Sep-2019 000000000
EP-3996762-A1 Method for generating cardiac tissue mimetics Pending 12-Jul-2019 0000000000
US-20220275336-A1 Method for generating cardiac tissue mimetics Pending 12-Jul-2019 0000000000
EP-3374510-A1 Tissue selective transgene expression Pending 11-Nov-2015 C12N15/86
To view Genome Biologics’s complete patent history, request access »

Genome Biologics Executive Team (3)

Name Title Board Seat Contact Info
Jonathan Ward Co-Founder & Chief Executive Officer
Maria Duda Ph.D Chief Operating Officer
Jaya Krishnan Ph.D Co-Founder & Chief Technology Officer
To view Genome Biologics’s complete executive team members history, request access »

Genome Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genome Biologics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Innovation Council Fund Venture Capital Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
To view Genome Biologics’s complete investors history, request access »

Ready to get started?

Request a free trial